![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/14/2881845/0/en/PepGen-Reports-First-Quarter-2024-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2024/03/13/2845838/0/en/PepGen-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/03/13/2845286/0/en/PepGen-Receives-U-S-FDA-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-for-PGN-EDO51-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2024/03/06/2841759/0/en/PepGen-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Corporate-Developments.html
https://www.globenewswire.com//news-release/2024/03/04/2839407/0/en/PepGen-Announces-Clearance-of-CTA-by-UK-Medicines-Healthcare-Products-Regulatory-Agency-to-Begin-CONNECT2-EDO51-a-Phase-2-Clinical-Trial-designed-to-support-potential-accelerated-a.html
https://www.globenewswire.com//news-release/2024/02/20/2831795/0/en/PepGen-Receives-U-S-FDA-Fast-Track-Designation-for-PGN-EDODM1-for-the-Treatment-of-Myotonic-Dystrophy-Type-1.html
https://www.globenewswire.com//news-release/2024/02/07/2825084/0/en/PepGen-Announces-Pricing-of-80-1-Million-Underwritten-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/01/17/2810588/0/en/Mary-Beth-DeLena-Joins-PepGen-as-General-Counsel-and-Secretary.html
https://www.globenewswire.com//news-release/2024/01/08/2805272/0/en/PepGen-Announces-First-Patient-Dosed-in-CONNECT1-EDO51-Phase-2-Clinical-Trial-of-PGN-EDO51-for-Duchenne-Muscular-Dystrophy-Patients-Amenable-to-Exon-51-Skipping.html